Bioreductive drugs in cancer therapy.
Stratford
I J
IJ
MRC Radiobiology Unit, Chilton, Didcot, UK.
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000975:Antioxidants / Q000008:administration & dosage; D015687:Cell Hypoxia / Q000187:drug effects*; D006801:Humans; D008920:Misonidazole / Q000031:analogs & derivatives / Q000627:therapeutic use; D009369:Neoplasms / Q000188:drug therapy*; D009593:Nitroimidazoles / Q000627:therapeutic use; D011355:Prodrugs / Q000627:therapeutic use; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use*; D000077704:Tirapazamine; D014227:Triazines / Q000627:therapeutic use
D000970:Antineoplastic Agents; D000975:Antioxidants; D009593:Nitroimidazoles; D011355:Prodrugs; D011838:Radiation-Sensitizing Agents; D014227:Triazines; C067834:RB 6145; D000077704:Tirapazamine; C041712:1-(2-nitro-1-imidazolyl)-3-aziridino-2-propanol; D008920:Misonidazole